Developers working on the Sputnik V Coronavirus vaccine have claimed that the shot is expected to offer immunity against the SARS-CoV-2 infection for at least 2 years, contrary to Pfizer that gives only 3 to 4 months of protection.
Head of the Gamaleya Research Institute of Epidemiology and Microbiology, Alexander Gintsburg said that the Pfizer and BioNTech vaccine is unlikely to offer protection beyond five months, while Sputnik V which is developed on the same platform which was also used for the Ebola vaccine, provides longer safety, Gintsburg told the Soloviev Live channel according to TASS.
Gintsburg added that Sputnik V has registered 96% efficacy, which is a step further up than 95% on the 42nd day after the first dose was administered. According to the institute, the Sputnik V vaccine hit the efficacy rate of 91.4 percent among those who were given two shots of the vaccine on the 28th day after the dose. Sputnik V currently received nod for its Phase III clinical trials and ongoing in Belarus, the UAE, Venezuela, and other countries, as well as Phase II-III in India.
The National Research Center for Epidemiology and Microbiology, N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) have made it public that the vaccine based on a safe and proven platform of human adenovirus vector immunity will be amounting to somewhere around $10.
“Results of the Sputnik V vaccine demonstrated during the Phase III clinical trials support our confidence in its high efficacy and complete safety for health. This is especially important when it comes to the beginning of large-scale vaccination of the population,” Alexander Gintsburg, Gamaleya Center Director highlighted. The vaccine is most effective in bringing down the scale of pandemic and creating a strong long-term immunity to Coronavirus infection.